Group 1: 恒瑞医药 - Company received approval for clinical trials of HRS-7172 tablets, a new anti-tumor small molecule inhibitor [1] - Subsidiary received approval for SHR-A2009, an antibody-drug conjugate targeting HER3 [1] - Company was established in April 1997, focusing on drug research, production, and sales [1] Group 2: 康德莱 - Controlling shareholder plans to transfer 5% of shares to strategic investor at a price of 10.81 yuan per share, totaling 236 million yuan [1] - Post-transfer, controlling shareholder's stake will decrease from 39.58% to 34.58% [1] - Company was established in July 1998, specializing in medical devices [2] Group 3: 中钢洛耐 - Shareholder plans to reduce holdings by up to 1% of total shares due to fund exit needs [3] - Company was established in August 2006, focusing on high-end refractory materials [3] Group 4: 瑞玛精密 - Subsidiary completed acquisition of land in Mexico for production operations, covering 52,300 square meters at a price of 3.4064 million USD [4] - Company was established in March 2012, specializing in precision metal stamping and related products [4] Group 5: 鸿博股份 - Company confirmed normal operations despite stock price fluctuations exceeding 20% over three trading days [5] - Company was established in June 1999, focusing on lottery services and high-end packaging [6] Group 6: 东芯股份 - Company completed stock trading risk investigation and resumed trading [7] - Company was established in November 2014, specializing in storage chip design and sales [7] Group 7: 凯迪股份 - Company stated that its robot products are still in development and will not generate revenue in the short term [8] - Company was established in August 1992, focusing on linear drive systems [8] Group 8: 诺唯赞 - Major shareholder plans to reduce holdings by up to 3% due to funding needs [9] - Company was established in March 2012, focusing on functional proteins and organic materials [9] Group 9: 君实生物 - Company received approval for clinical trials of JT118 injection, a "two-in-one" recombinant protein vaccine for monkeypox [10] - Company was established in December 2012, focusing on new drug research and related services [10] Group 10: 赛力斯 - Company reported August sales of 45,818 vehicles, with a 19.57% increase in new energy vehicle sales [11] - Company was established in September 2012, focusing on automotive research and sales [11] Group 11: 燕东微 - Major shareholder plans to reduce holdings by up to 1% due to management needs [13] - Company was established in October 1987, focusing on semiconductor products and services [13] Group 12: 中百集团 - Company reported cumulative litigation and arbitration amounts of approximately 262 million yuan over the past 12 months [14] - Company was established in January 1990, focusing on retail business [14] Group 13: 金开新能 - Company received 939 million yuan in renewable energy subsidies, with a 341.67% increase year-on-year [15] - Company was established in March 1997, focusing on renewable energy development and operation [15] Group 14: *ST天茂 - Company plans to terminate stock listing and initiate cash option mechanism for shareholders [16] - Company was established in November 1993, focusing on various insurance services [16] Group 15: 宁德时代 - Company repurchased 8.69 million A-shares for a total of 2.131 billion yuan [17] - Company was established in December 2011, focusing on battery research and production [17] Group 16: 山西高速 - Controlling shareholder plans to increase holdings by 30 to 60 million yuan [18] - Company was established in February 1996, focusing on highway management [18] Group 17: 青岛银行 - Major shareholder plans to increase holdings by 233 to 291 million shares [19] - Company was established in November 1996, focusing on banking services [19] Group 18: 格力电器 - Major shareholder completed share increase of 46.38 million shares for 2.099 billion yuan [20] - Company was established in December 1989, focusing on air conditioning production and sales [20] Group 19: 中国石油 - Company plans to transfer 541 million A-shares to China Mobile Group to enhance strategic cooperation [21] - Company was established in November 1999, focusing on oil and gas exploration and production [21] Group 20: 镇洋发展 - Company announced a merger plan with Zhejiang Huhangyong Highway Co., with a share exchange ratio of 1:1.08 [22] - Company was established in December 2004, focusing on chemical products [22]

Core Viewpoint - Zhejiang Hu-Hang-Yong (00576) is proposing a share swap to absorb and merge with Zhenyang Development (603213), aiming for a dual listing in both A-share and H-share markets, which is expected to enhance funding sources for highway construction and capitalize on development opportunities in the Yangtze River Delta [1] Group 1: Share Swap and Listing Details - The company plans to issue A-shares at a price of 13.5 RMB, while the share swap price for Zhenyang Development is set at 14.58 RMB, with a conversion ratio of 1 share of Zhenyang Development to 1.08 A-shares [1] - The transaction involves the issuance of 216 million A-shares, totaling 4.492 billion A-shares that will be applied for listing on the Shanghai Stock Exchange [1] - The issuance price represents a premium of 119.01% compared to the closing price on September 2, based on the exchange rate of 1 HKD to 0.91183 RMB [1] Group 2: Strategic Implications - The merger through a share swap is expected to broaden the company's funding sources, providing financial support for highway construction projects [1] - This strategic move is aligned with the company's goal to leverage development opportunities in the Yangtze River Delta region [1]

Core Viewpoint - Zhejiang Huhangyong (00576) is proposing a share swap merger with Zhenyang Development to achieve a dual listing in both A-share and H-share markets, which is expected to enhance funding sources for highway construction and capitalize on development opportunities in the Yangtze River Delta [1] Group 1: Company Actions - Zhejiang Huhangyong's share price increased by nearly 4%, reaching HKD 7.02, with a trading volume of HKD 28.62 million [1] - The company plans to issue A-shares at a price of RMB 13.5, while the swap price for Zhenyang Development shares is set at RMB 14.58, with a conversion ratio of 1 share of Zhenyang Development to 1.08 A-shares of Zhejiang Huhangyong [1] - A total of 216 million A-shares will be issued, along with 4.492 billion A-shares from the conversion of existing domestic shares, which will be listed on the Shanghai Stock Exchange [1] Group 2: Financial Metrics - The issuance price represents a premium of 119.01% compared to the closing price on September 2, based on the exchange rate of 1 HKD to 0.91183 RMB [1] - The merger is expected to provide significant financial support for highway construction projects [1]

Group 1 - The core point of the article is that Zhenyang Development (603213) announced a major asset restructuring plan on September 2, where Zhejiang Huhangyong Expressway Co., Ltd. intends to issue A-shares to all shareholders of Zhenyang Development for a share swap merger [1] - Zhejiang Huhangyong is a Hong Kong-listed company primarily engaged in the construction, operation, maintenance, and management of high-grade highways [1] - Following the completion of the merger, Zhenyang Development will terminate its listing and eventually cancel its legal entity status, while Zhejiang Huhangyong will apply for the A-shares issued in this merger to be listed and traded on the Shanghai Stock Exchange [1] Group 2 - The share swap ratio for the merger is set at 1:1.08, meaning that for every 1 share of Zhenyang Development, shareholders will receive 1.08 shares of the newly issued A-shares of Zhejiang Huhangyong [1] - Zhenyang Development's A-shares, convertible bonds, and convertible bond conversions will resume trading on September 3, following a trading suspension [1] - Notably, the company's stock hit the daily limit up on the day before the trading suspension [1]

镇洋发展(603213)9月2日晚间披露重大资产重组预案，浙江沪杭甬高速公路股份有限公司（简称"浙江沪杭甬"）拟向公司全体股东发行A股股份换股吸收 合并公司。 此次交易的特殊之处在于，浙江沪杭甬是一家港股上市公司。资料显示，浙江沪杭甬是一家主要从事建设、经营、维修及管理高等级公路的投资控股公 司。镇洋发展为浙江省交通投资集团有限公司控股子公司，是一家化工企业。 换股吸收合并完成后，镇洋发展将终止上市并最终注销法人资格。浙江沪杭甬作为存续公司，浙江沪杭甬为此次吸收合并发行的A股股票及原内资股将申 请在上交所主板上市流通。 此次合并的换股比例为1：1.08，即镇洋发展换股股东所持有的每1股镇洋发展A股股票可以换得1.08股浙江沪杭甬本次发行的A股股票。 镇洋发展A股股票、可转债、可转债转股将于9月3日复牌。值得一提的是，公司股票在停牌前一天涨停。 ...

证券代码：603213 证券简称：镇洋发展 公告编号：2025-045 转债代码：113681 转债简称：镇洋转债 浙江沪杭甬高速公路股份有限公司（以下简称"浙江沪杭甬" ）、镇 浙江镇洋发展股份有限公司 第二届监事会第十六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和 完整性承担法律责任。 一、监事会会议召开情况 浙江镇洋发展股份有限公司（以下简称"公司"或"镇洋发展" ）第二届监事会第十六次会议于2025年9月2日在浙江省宁波市镇海 区宁波石化经济技术开发区海天中路655号712会议室以现场方式召开。 会议通知已于2025年8月27日以书面形式送达。本次会议应出席监事 议的召集、召开和表决程序均符合《公司法》《公司章程》及相关 法律法规的规定。 二、监事会会议审议情况 本次会议对以下议案进行逐项审议并表决，形成如下决议： （一）审议通过《关于本次交易符合上市公司重大资产重组相关 法律法规规定的议案》 洋发展经协商，拟由浙江沪杭甬向公司全体股东发行 A 股股份换股吸 收合并镇洋发展（以下简称"本次交易" ）。根据《上市公司重大资 ...

证券代码：603213 证券简称：镇洋发展 公告编号：2025-046 转债代码：113681 转债简称：镇洋转债 浙江镇洋发展股份有限公司 关于停牌前一个交易日前十大股东和前十大流通 股东持股情况的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和 完整性承担法律责任。 根据《上海证券交易所上市公司自律监管指引第 4 号——停复 牌》的相关要求，现将公司停牌前一个交易日（即 2025 年 8 月 19 日） 前十大股东的名称及持股数量、前十大流通股股东的名称及持股数量 等信息披露如下： 一、公司前十大股东持股情况 序号 股东名称 持股数量（股） 持股比例（%） 宁波市镇海区海江投资发展有 限公司 宁波汇海企业管理合伙企业 （有限合伙） 宁波海江企业管理合伙企业 （有限合伙） 二、公司前十大流通股东持股情况 序号 股东名称 持股数量（股） 持股比例（%） 宁波市镇海区海江投资发展有 限公司 宁波汇海企业管理合伙企业 浙江镇洋发展股份有限公司（以下简称"公司"） 、浙江沪杭甬高 速公路股份有限公司（以下简称"浙江沪杭甬"）正在筹划由浙江沪 杭甬向本 ...

公司于 2025 年 9 月 2 日召开第二届董事会第二十七次会议，审议通过 了《关于 <浙江沪杭甬高速公路股份有限公司换股吸收合并浙江镇洋发展股> 份有限公司暨关联交易预案>及其摘要的议案》等与本次交易相关的议案， 具体内容详见公司同日刊登在上海证券交易所网站（www.sse.com.cn）的 相关公告。 证券代码：603213 证券简称：镇洋发展 公告编号：2025-047 转债代码：113681 转债简称：镇洋转债 浙江镇洋发展股份有限公司 关于暂不召开股东会审议本次交易相关事项的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和 完整性承担法律责任。 浙江镇洋发展股份有限公司（以下简称"公司" ）、浙江沪杭甬高速公 路股份有限公司（以下简称"浙江沪杭甬" ）正在筹划由浙江沪杭甬向本公 司全体股东发行 A 股股份换股吸收合并本公司。 根据《上市公司重大资产重组管理办法》 《上市公司监管指引第9号—— 上市公司筹划和实施重大资产重组的监管要求》 《公开发行证券的公司信息 披露内容与格式准则第26号——上市公司重大资产重组》等相关法律、法 规和 ...

Group 1 - The core viewpoint of the article is that Zhejiang Huhangyong intends to merge with Zhejiang Zhanyang Development through a share exchange, which is in compliance with regulatory requirements [1][2] - The board of directors of Zhejiang Zhanyang Development has conducted a careful analysis and believes that the transaction meets the requirements outlined in the regulatory guidelines [1][2] - The transaction will allow the surviving company to inherit all assets, liabilities, and rights of Zhejiang Zhanyang Development, enhancing its independence and risk resistance [2] Group 2 - Both Zhejiang Huhangyong and Zhejiang Zhanyang Development do not have any issues that would affect their legal existence or restrict the transaction [2] - The transaction aims to highlight the main business and improve the ability to manage risks, which is beneficial for the surviving company [2] - The board has indicated that all necessary approvals for the transaction have been disclosed in detail, along with specific risks related to potential non-approval [1]

Group 1 - The core point of the article is that Zhejiang Zhenyang Development Co., Ltd. and Zhejiang Huhangyu Expressway Co., Ltd. are planning a share swap merger, with Huhangyu issuing A-shares to acquire Zhenyang [1][3] - The board of directors of Zhenyang Development confirms that all necessary legal procedures for the transaction have been completed in accordance with relevant laws and regulations [3][5] - The transaction requires several approvals, including from state-owned asset supervision authorities, both companies' boards, shareholder meetings, and regulatory bodies such as the Shanghai Stock Exchange and the China Securities Regulatory Commission [4][5] Group 2 - The board emphasizes the importance of confidentiality and has implemented measures to limit the knowledge of sensitive information related to the transaction [1][3] - The legal documents submitted for the transaction are guaranteed to be true, complete, and free from misleading statements or significant omissions [5] - The transaction is subject to various regulatory approvals, including potential antitrust reviews and necessary consents from relevant authorities [4]